Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in HFrEF with Prosthetic Heart Valves
NCT07192341Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Kafrelsheikh University. Primary endpoint: Effective rate at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07192341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192341.